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2 Naturally occurring polyphenolic compounds are of medicinal importance because of their unique 22 antioxidant, anticancer and chemopreventive properties. Baicalein, a naturally occurring polyhydroxy 23 flavonoid possessing a diverse range of pharmacological activities, has been used in traditional 24 medicines for treatment of various ailments. Apart from its isolation from natural sources, its synthesis 25 has been reported via multi-step chemical approaches. Here we report a preparative-scale 26 biotransformation, using whole yeast cells stably expressing human cytochrome P450 1A1 (CYP1A1) 27 enzyme, that allows regioselective C6-hydroxylation of 5,7-dihydroxyflavone (chrysin) to form 5,6,7-28 trihydroxyflavone (baicalein). Molecular modelling reveals why chrysin undergoes such specific 29 hydroxylation mediated by CYP1A1. More than 92% reaction completion was obtained using a shake-30 flask based process that mimics fed-batch fermentation. Such highly efficient selective hydroxylation, 31 using recombinant yeast cells, has not been reported earlier. Similar CYP-expressing yeast cell-based 32 systems are likely to have wider applications in the syntheses of medicinally important polyphenolic 33 compounds. 34 INTRODUCTION 39 Baicalein (5,6,7-trihydroxyflavone) (1) was originally isolated from the roots of Scutellaria baicalensis 40 (Chinese skullcap) which is used for treatment of chronic hepatitis, inflammatory diseases, tumors, and 41 diarrhea in China, Korea, Taiwan, and Japan. 1 Its isolation has also been reported from another plant, 42
Oroxylum indicum (Indian trumpet flower). 2 Baicalein is known for its anticancer properties in various 43 cancer types 2-22 including pancreatic, gastric and colorectal cancers, multiple myeloma, head and neck 44 cancer, and breast cancer. 23, 24 Baicalein is also considered as an anti-inflammatory 25, 26 that generally 45 protects against oxidative stress, 27 more specifically in cardiac cells, 28 and in cisplatin-induced acute 46 kidney injury. 29 Because of its wide-ranging medicinal applications, an industrial scale protocol for its 47 production would be considered as important. 48
Baicalein has primarily been produced via five approaches: (a) single-step hydrolysis of the natural 49 product baicalin, a glycoside, 30 (b) 4-step total synthesis from a cinnamic acid derivative, 31 (c) 4-step 50 total synthesis from 3,4,5-trimethoxyphenol, 32 (d) 3-step total synthesis from 2,4,5,6-51 tetrahydroxyacetophenone, 33 and (e) 6-step synthesis from chrysin 34 involving methylation, bromination, 52 acylation, nucleophilic replacement of Br with OMe, followed by de-acylation and demethylation as key 53 steps. 54
Selective transformation, using efficient biocatalysts, of a low value phytochemical to high value 55 phytochemical is an exciting area of bioorganic chemistry. Sordon and coworkers 35 have reported 56 biotransformations of natural flavonoids naringenin, hesperetin, chrysin, apigenin, luteolin, quercetin, 57 epicatechin, and biochanin A using the natural yeast, Rhodotorula glutinis. This approach produced 58 norwogonin (5,7,8-trihydroxyflavone) from chrysin (5,7-dihydroxyflavone). Here we report a 59 preparative scale process for biotransformation of chrysin to baicalein, via selective C6-hydroxylation 60 using recombinant human cytochrome P450-1A1 (CYP1A1) enzyme expressed within baker's yeast 61 (Saccharomyces cerevisiae) cells. This is the first single-step protocol for a high-yield conversion of 62 4 chrysin to baicalein and, therefore, may serve as a simple and cheap strategy for production of baicalein 63 in an industrial scale. 64
MATERIALS AND METHODS 65
General. All chemicals were obtained from Sigma-Aldrich and were used as received. 1 0.25 (10), 9.00 (100), 10.00 (100), 11.00 (10), 12.00 (10). PDA range: 220 nm to 400 nm; flow rate: 0.3 78 mL/min. 79 Biotransformation experiment. Yeast strains, each of which contain two copies of human CYP1A1 or 80 CYP1A2 genes, downstream of the ADH2 promoter, integrated into chromosomal loci of the genome of 81 the yeast strain W303-1a (ATCC 208352), were used for biotransformation (Section S2 of supporting 82 information). Expressed CYP1A1 and CYP1A2 proteins were confirmed by Western blotting 83 (supporting information-S4). The strains, from frozen stocks, were revived in 250 mL Erlenmeyer 84 baffled flasks containing 50 mL YPD (Yeast, Peptone, Dextrose) medium with composition (g/L): 85 peptone 20; yeast extract 10; glucose 15.0, pH 6.0. The flasks were shaken at 200 rpm, at 28 °C. Three 86 consecutive YPD pre-cultures were grown for high biomass production, before addition of the substrate 87 to cells grown in SD (Synthetic Defined) medium. Typically, loopful of CYP-containing freshly grown 88 yeast cells was inoculated in a 500 mL Erlenmeyer baffled flask separately containing 100 mL YPD 89 medium (pre-culture -1) at 28 °C for 24 h. The cells were harvested after 24 h and inoculated into a new 90 500 mL baffled flask containing 100 mL YPD medium (pre-culture -2) at 30 °C for 18 h. The process 91 was repeated three times for the cells to reach an OD 600 , of ~90. 92
The harvested cells, ~3.0 mL (OD 600 , ~90), were inoculated in 50 mL of minimal SD medium contained 93 in a 1 L baffled flask. Composition of SD medium (g/L): dextrose 1.0; dipotassium phosphate 7.0; 94 monopotassium phosphate 2.0; sodium citrate 0.50; magnesium sulphate 0.10; ammonium sulphate 1.0, 95 pH 7.0 ± 0.2 at 28 °C. Initially, reaction was carried out with 0.2 mg/mL of chrysin. Later, the chrysin at 96 different concentrations viz. 0.2, 1, 2, 5 and 10 mg/mL were incubated in 50 mL of SD medium (DMSO 97 was used for initial dissolution of the compound, and keeping the DMSO concentration < 0.5% in final 98 reaction medium) for 72 h at 28 °C, 200 rpm. After every 24 h, the medium was replenished with 1.5% 99 w/v of glucose. For optimization of incubation time, the SD cell culture media were harvested after 24, 100 48, 72, 96, 120, 144 and 160 h, and were then analysed on TLC and HPLC/ LC-MS to monitor the 101 yields of biotransformation at each time point. 102
Isolation and characterization of baicalein. The reaction media was extracted with ethyl acetate (3 103 times). The combined ethyl acetate layer was concentrated on vacuo-rotavapor to obtain crude extracts 104 that contained the biotransformation product. The crude residue was loaded on a reverse phase (C18) 105 silica gel column packed in water. The crude extract was loaded on the column by making a slurry with 106 C18 silica gel mesh 200-400 (Sigma-Aldrich, product no. 377635). The column was then eluted with 107 increasing concentrations of methanol in water. The desired product was collected at 50% methanol in 108 water. Evaporation of the solvent gave a yellow solid which was characterized as baicalein (1). Yellow Eukaryotic baker's yeast cells were chosen because they can grow as rapidly as bacterial cells and they 125 are as amenable as bacteria for scale-up in fermentors. Using Baker's yeast cells, we have developed an 126 efficient technology for stable expression of human CYP enzymes within these cells. Using this 127 platform, recombinant baker's yeast cells can continue to express CYPs in shake flasks, over a week or 128 more, with increasing activities, under conditions that mimic fed-batch growth (Supporting Information; 129 S1). Microsomal CYP enzymes, isolated from these same recombinant yeast cells, have successfully 130 7 cytochrome P450 family 1 enzymes CYP1A1 and CYP1A2 are reported to oxidize dietary flavonoids, 40-136 42 herein we chose two yeast-expressed enzymes of the CYP1 sub-family (i.e. CYP1A1 and CYP1A2) 137 as biocatalysts. 138
Two recombinant yeast strains, each containing two chromosomally integrated copies of CYP1A1 and 139
CYP1A2 genes under the control of the ethanol-inducible alcohol dehydrogenase 2 (ADH2) promoter, 140 were created to enable stable and reproducible biotransformation reactions (plasmid maps shown in 141
Supporting Information, S2). The ADH2 promoter is repressed in the presence of glucose. The aim was 142 that recombinant yeast cells, containing stably integrated CYP expression cassettes, would be grown 143 initially in complete YPD medium (containing 2% glucose) to obtain large optical density, measured at a 144 wavelength of 600 nm (OD 600 ) of ~90, in shake flasks. This would occur without any plasmid loss and 145 would be achieved over 3 days through repetitive replenishment of glucose, every 24 h, in the non-146 selective highly nutritious YPD medium. Cells grown in YPD (Figure 1a ) would then be re-suspended 147 in minimal selective SD medium (pH 7.0), supplemented with 1.5% of glucose, for the 148 biotransformation reaction. It was thought that rich full YPD medium may not be appropriate for 149 biotransformation since there is a possibility of substrate binding to its ingredients. 150
For initial optimization, reactions were performed in SD with 10 mg of chrysin in baffled flasks shaking 151 at 200 rpm for 72 h, at 28 °C (Figure 1b ). After every 24 h, the medium was replenished with fresh 152 glucose to a final concentration of 1.5%. Glucose was exhausted after 12 h of growth of yeast cells when 153 it was converted to ethanol. Hence, the ethanol-inducible ADH2 promoter was fully induced every 12 h 154 before more glucose was added to the medium for further rounds of expression. 155 The same product was formed using both the enzymes, CYP1A1 and CYP1A2, expressed within yeast 161 cells. However, conversion of substrate to product was better with CYP1A1. Therefore, for subsequent 162 scale-up experiments, only CYP1A1-expressing yeast cells were used for biotransformation. 163
Scale up and optimization of biotransformation reaction. Scale-up was performed as above; cells 164 were at first cultivated in non-selective YPD media for 72 h, with fresh glucose (2%) being added every 165 24 h. Cells were re-suspended in selective SD minimal medium. Chrysin at different concentrations viz. 166 0.2, 1, 2, 5 and 10 mg/mL were dissolved in DMSO and further incubated in 50 mL of SD medium 167 (keeping the DMSO concentration < 0.5%) for 72 h at 28 °C, 200 rpm. The chrysin-containing cell 168 culture media were replenished with glucose every 24 h to a final concentration of 1.5%. The reaction 169 using chrysin at concentration of 2 mg/mL (100 mg of chrysin) was observed to be the most efficient. 170
With 5 and 10 mg/mL concentrations, incomplete biotransformation occurred, probably because the 171 small number of cells, used for growth in these specific experiments, was inhibited by the substrate. 172
Based on these results, it was decided to optimize the time period for biotransformation. For this, we 173 The relative percentages (AUC) of chrysin and baicalein at different time intervals are depicted in Figure  182 3. As shown in Figure 3 , the percentage conversion of chrysin to baicalein increased with time. Isolation and characterization of baicalein. Initial isolation attempts using normal phase silica gel 188 column chromatography showed significant loss in the product yield. Therefore, we attempted reverse 189 phase C18 silica gel column chromatography where water-methanol was used as the mobile phase. The 190 product was isolated at 50% methanol in water and was characterized by spectral analysis and by 191 comparison of its TLC with reference sample. 192
The 1 H NMR of chrysin contains a typical bunch of three singlets at chemical shift values in the range of 193 6 to 7 ppm. These three singlets at δ 6.24, 6.49 and 6.74 ppm correspond to the protons present at C6, 194 C8 and C3 positions. The C6-proton appears with an up-field shift in comparison to two other aromatic 195 protons at C3 and C-6, because of the shielding effect from two adjacent C5 and C7 hydroxyls. It is 196 obvious that the hydroxylation reaction is possible, either on A or C ring. Since there was no change in 197 the chemical shift value pattern of C ring (δ 7.91, dd, 2H and δ 7.48, m, 3H), it would indicate that the 198 C-ring is intact and no hydroxylation had taken place on this ring. The hydroxylation on A ring has two 199 possibilities, either C6-or C8 hydroxylation. Hydroxylation at C6-position will form baicalein (5,6,7-200 trihydroxyflavone) whereas hydroxylation at C8-position will form norwogonin (5,7,8-201 trihydroxyflavone) as a product. It was interesting to see that, in the 1 H NMR of the obtained product, 202 the up-field singlet (δ 6.24 ppm) disappeared. This singlet peak in chrysin corresponds to the proton 203 present at C6-position. This gave us a clear indication that hydroxylation occurred at the C6-position, 204 which means that the product is 5,6,7-trihydroxyflavone. This is the naturally occurring flavone, 205 commonly named as 'baicalein'. Furthermore, on comparison of the 1 H NMR of the obtained product 206 with norwogonin, 35 the possibility of norwogonin as the product was ruled out. In literature, the 207 biotransformation of chrysin using natural yeast, Rhodotorula glutinis yielded C-8 hydroxylated product 208 10 norwogonin, 35 however in the present study, C-6 hydroxylated product (baicalein) was formed, which 209 may be possibly because of the regio-specificity of the CYP1A1 enzyme. 210
Mass analysis of the isolated product showed m/z peak at 271 in ES+ve mode, which matched with the 211 predicted product. The final confirmation of the assigned product was done by co-TLC and HPLC 212 analysis with the reference standard of baicalein (CAS number: 491-67-8)' purchased from Sigma-213
Aldrich. TLC images as well as HPLC analysis clearly matched the reference standard (TLC images are 214 shown in Supporting Information -S3). 215
The LC-MS analysis was also performed for the extract as well as isolated baicalein (Figure 4) . 216 Chrysin Baicalein
CYP1A1expressing yeast cells

